Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: Moderna And Pfizer Respond To Vaccine Trial Transparency Demands

Plus: Amgen Helps Lilly With Antibody Manufacturing

Executive Summary

Moderna led by releasing the trial protocol for its COVID-19 vaccine study, followed by Pfizer, as industry faces demands for transparency.

You may also be interested in...



‘Reckless’ State Campaigns Seek To Undermine Western COVID-19 Vaccines

China, Iran and especially Russia have launched campaigns aimed at undermining confidence in Western vaccines, especially Pfizer’s, according to two reports.

‘Reckless’ State Campaigns Seek To Undermine Western COVID-19 Vaccines

China, Iran and especially Russia have launched campaigns aimed at undermining confidence in Western vaccines, especially Pfizer’s, according to two reports.

Lilly Signs US Bamlanivimab Contract, Raising Unanswered Allocation Considerations

The price of the antibody monotherapy for COVID-19 will be $1,250 per vial for wealthy countries. CEO David Ricks outlined the company's guidelines for pricing and distributing a limited supply.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142982

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel